LD50 IP 325 mg/Kg (rat).
LD50 IV 1740 mg/Kg (mouse).
LD50 oral >5000 mg/Kg (rat).
Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the vagina. It is being also for the prevention and treatment of osteoporosis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Esterified estrogens. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Esterified estrogens. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Esterified estrogens. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Esterified estrogens. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Esterified estrogens. |
| Lenalidomide | Esterified estrogens may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Esterified estrogens is combined with Ospemifene. |
| Ropinirole | Esterified estrogens may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Thalidomide | Esterified estrogens may increase the thrombogenic activities of Thalidomide. |
| Cetuximab | Esterified estrogens may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Esterified estrogens may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Esterified estrogens may increase the thrombogenic activities of Omalizumab. |
| Gemtuzumab ozogamicin | Esterified estrogens may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Esterified estrogens may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Trastuzumab | Esterified estrogens may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Esterified estrogens may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Esterified estrogens may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Esterified estrogens may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Esterified estrogens may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Esterified estrogens may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Esterified estrogens may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Esterified estrogens may increase the thrombogenic activities of Alemtuzumab. |
| Capromab pendetide | Esterified estrogens may increase the thrombogenic activities of Capromab pendetide. |
| Efalizumab | Esterified estrogens may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Esterified estrogens may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Esterified estrogens may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Esterified estrogens may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Esterified estrogens may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Esterified estrogens may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Esterified estrogens may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Esterified estrogens may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Esterified estrogens may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Esterified estrogens may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Esterified estrogens may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Esterified estrogens may increase the thrombogenic activities of Pexelizumab. |
| Epratuzumab | Esterified estrogens may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Esterified estrogens may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Esterified estrogens may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Esterified estrogens may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Esterified estrogens may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Esterified estrogens may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Esterified estrogens may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Esterified estrogens may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Esterified estrogens may increase the thrombogenic activities of Bavituximab. |
| CR002 | Esterified estrogens may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Esterified estrogens may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Esterified estrogens may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Esterified estrogens may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Esterified estrogens may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Esterified estrogens may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Esterified estrogens may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Esterified estrogens may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Esterified estrogens may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Esterified estrogens may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Esterified estrogens may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Esterified estrogens may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Esterified estrogens may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Esterified estrogens may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Esterified estrogens may increase the thrombogenic activities of Ustekinumab. |
| PRO-542 | Esterified estrogens may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Esterified estrogens may increase the thrombogenic activities of TNX-901. |
| Inotuzumab ozogamicin | Esterified estrogens may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| RI 624 | Esterified estrogens may increase the thrombogenic activities of RI 624. |
| Stamulumab | Esterified estrogens may increase the thrombogenic activities of MYO-029. |
| CT-011 | Esterified estrogens may increase the thrombogenic activities of CT-011. |
| Leronlimab | Esterified estrogens may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Esterified estrogens may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Esterified estrogens may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Esterified estrogens may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Esterified estrogens may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Esterified estrogens may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Esterified estrogens may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Esterified estrogens may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Esterified estrogens may increase the thrombogenic activities of Lumiliximab. |
| Ipilimumab | Esterified estrogens may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Esterified estrogens may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Esterified estrogens may increase the thrombogenic activities of Clenoliximab. |
| BIIB015 | Esterified estrogens may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Esterified estrogens may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Esterified estrogens may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Esterified estrogens may increase the thrombogenic activities of Elotuzumab. |
| Carotuximab | Esterified estrogens may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Esterified estrogens may increase the thrombogenic activities of XmAb 2513. |
| Lucatumumab | Esterified estrogens may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Esterified estrogens may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Esterified estrogens may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Esterified estrogens may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Esterified estrogens may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Esterified estrogens may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Esterified estrogens may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Esterified estrogens may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Esterified estrogens may increase the thrombogenic activities of Reslizumab. |
| Teplizumab | Esterified estrogens may increase the thrombogenic activities of Teplizumab. |
| Catumaxomab | Esterified estrogens may increase the thrombogenic activities of Catumaxomab. |
| Mepolizumab | Esterified estrogens may increase the thrombogenic activities of Mepolizumab. |
| Denosumab | Esterified estrogens may increase the thrombogenic activities of Denosumab. |
| Volociximab | Esterified estrogens may increase the thrombogenic activities of Volociximab. |
| Ofatumumab | Esterified estrogens may increase the thrombogenic activities of Ofatumumab. |
| Belimumab | Esterified estrogens may increase the thrombogenic activities of Belimumab. |
| Raxibacumab | Esterified estrogens may increase the thrombogenic activities of Raxibacumab. |